Open Your FREE Demat Account Now!

Ipca Laboratories Ltd. Share Price

NSE
BSE

NSE : IPCALAB

BSE : 524494

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹1,797.60

High

₹1,949.90

Price Summary

Previous Close ₹1,918.90
Day's Range ₹1,797.60 - ₹1,949.90
Open ₹1,810.00
52 Week Range ₹1,251.60 - ₹2,038.00
Volume 5,11,090
Market Cap ₹0.05
Previous Close ₹1,916.80
Day's Range ₹1,791.80 - ₹1,949.00
Open ₹1,791.80
52 Week Range ₹1,252.95 - ₹2,039.30
Volume 17,513
Market Cap ₹0.05

Stocks Summary

Trade Value ( ₹ in Lacs) 9,807.31
Market Cap (₹ in Mn) 0.05
Dividend Yield(%) 0.33
Price/Earning (TTM) 35.16
TTM EPS (₹) 51.63
P/E Ratio 35.64
Book Value(₹) 5.43
PAT Margin (%) 12.35
Face Value (₹) 1.00
ROCE(%) 19.41
Trade Value ( ₹ in Lacs) 335.69
Market Cap (₹ in Mn) 0.05
Dividend Yield(%) 0.33
Price/Earning (TTM) 35.16
TTM EPS (₹) 51.63
P/E Ratio 35.64
Book Value(₹) 5.43
PAT Margin (%) 12.35
Face Value (₹) 1.00
ROCE(%) 19.41

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 17469.0 66779.2
Expenses N/A N/A
PBT 3567.5 9997.7
Operating profit 0.0 0.0
Net profit 2620.4 6507.6

Shareholding Pattern

Promoters (% Holding)

44.72%

Mutual funds (% Holding)

31.07%

Non-Institution (% Holding)

7.15%

FI/Banks/Insurance (% Holding)

4.76%

Government (% Holding)

0.00%

FII

11.52%

About Ipca Laboratories Ltd.

Founded 1949
Managing Director Pranay Godha
NSE Symbol IPCALAB

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,18,683.95 1,745.00 1,583.70 - 1,583.70
Divi's Laboratories Ltd. 2,41,310.94 9,150.00 5,647.50 - 5,647.50
Torrent Pharmaceuticals Ltd. 1,73,078.79 4,527.55 3,532.60 - 3,532.60
Laurus Labs Ltd. 1,11,433.99 2,012.00 901.40 - 901.40
Lenskart Solutions Ltd. 1,11,141.66 637.35 0.00 - 0.00
Zydus Lifesciences Ltd. 1,11,022.18 1,117.30 835.50 - 835.50
Apollo Hospitals Enterprise Ltd. 1,10,757.32 7,604.95 6,696.50 - 6,696.50
Cipla Ltd. 1,07,527.58 1,313.80 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,03,667.29 1,237.65 1,101.00 - 1,101.00
Mankind Pharma Ltd. 93,013.62 2,281.00 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Aug
17
2026
EQUITY Posted on Aug 17th 2026

Ipca Laboratories informs about analyst meet outcome

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has enclosed transcript of Conference Call which was held on Friday, 14th August, 2026 from 15:30 hrs IST to discuss the Company’s Q1FY27 earnings and business update.
The above information is a part of company’s filings submitted to BSE.  
Read More
Jul
28
2026
EQUITY Posted on Jul 28th 2026

Ipca Laboratories informs about board meeting

Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Thursday, 13th August, 2026, to consider and take on record the standalone and consolidated unaudited financial results of the Company for the 1st quarter ended 30th June, 2026 of the financial year 2026-27. Further, with reference to the above meeting of the Board of Directors, it has already informed vide its letter dated 22nd June, 2026 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from 1st July, 2026 and until 48 hours after the declaration of the Company’s unaudited financial results for the 1st quarter ended 30th June, 2026 i.e., till 15th August, 2026.

The above information is a part of company’s filings submitted to BSE.

Read More
Oct
21
2026
EQUITY Posted on Oct 21st 2026

Shanmuga Hospital informs about updates

Shanmuga Hospital has informed that the Company has officially launched its ‘Shanmuga 360’ mobile application for commercial use on 20 October 2026. Shanmuga 360 is a digital healthcare mobile application developed to provide patients with convenient access to various healthcare services through a single digital platform. The application is designed to facilitate access to healthcare services, including appointment-related services, laboratory tests, second opinions, ambulance booking, medicine purchase options and home healthcare services, subject to availability and service coverage. The official commercial launch marks an important step in the Company's digital healthcare initiatives, aimed at enhancing patient convenience and improving accessibility to healthcare services.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
21
2026
EQUITY Posted on Oct 21st 2026

Zydus Lifesciences informs about press release

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 21, 2026, titled ‘Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity’. The contents of the press release give full details.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
21
2026
EQUITY Posted on Oct 21st 2026

Bharat Parenterals informs about newspaper advertisements

Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bharat Parenterals has informed that it enclosed copies of newspaper advertisements published in Business Standard (English) and Vadodara Samachar (Gujarati) on April 29, 2026 regarding proposed transfer of shares pursuant to the SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026 allowing the opening of a special window for re-lodgement of transfer of shares in physical form. The advertisement is also being made available on the Company’s website at www.bplindia.in.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Ipca Laboratories Ltd. ?

The current share price of Ipca Laboratories Ltd. is ₹1,918.90 as of 2026-10-21.

The market capitalisation of Ipca Laboratories Ltd. is ₹46,049.85 as of 2026-10-19.

The 1-year return of Ipca Laboratories Ltd. is 647.90% as of 2026-10-21.

The P/E ratio of Ipca Laboratories Ltd. is 35.64 as of 2026-10-21.

The 52-week high and low of Ipca Laboratories Ltd. are ₹2,038.00 and ₹1,251.60, respectively, as of 2026-10-21.

The dividend yield of Ipca Laboratories Ltd. is 0.3306% as of2026-10-19.

You can buy Ipca Laboratories Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Ipca Laboratories Ltd. is Pranay Godha.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

Which healthcare formulations and products are manufactured by Ipca Laboratories Ltd.?

Ipca Laboratories Ltd. manufactures a vast array of active pharmaceutical ingredients (APIs) and finished drug formulations. The company holds dominant global market shares in producing anti-malarial, rheumatology, and cardiovascular medications, serving both domestic retail and heavy international export markets.

Ipca Laboratories Ltd. works with global entities by exporting heavily vertically integrated APIs and formulations to over 100 countries. It partners with domestic hospitals and clinics through a massive medical representative network that ensures widespread availability of its specialised generic drugs.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore